Background: Myocardial infarction and stroke represent a major public health problem in most developing countries. This study explores genetic predisposition of acute myocardial infarction in the Czech population. Methods and Results: Genome-wide expression study used matched case-control design. Peripheral blood samples of the controls were matched to those of cases based on gender, age, status of diabetes mellitus and smoking status. Six months cardiovascular survival status of the cases was used to identify two distinct subgroups among the cases. Linear models for microarray data were employed to identify differential gene expression. Shrunken centroids technique helped in identifying the subsets of differentially expressed genes with predictive properties in independent samples. Predictive properties were evaluated using bootstrap sampling. Sixty transcripts were found to be both clinically and statistically differentially expressed among the cases not surviving the six months follow-up period relative to controls, while no such transcripts were observed among other surviving cases.
Introduction
Morbidity and mortality from atherosclerotic complications, such as acute myocardial infarction and stroke, continue to represent major public health issue in most developing countries. They are caused by multiple environmental and genetic factors and the interaction between them. While there are clinical risk factors known to be associated with the incidence of acute myocardial infarction, genetic profile of an individual may represent additional factors independently associated with the incidence of this outcome.
Genome-wide expression profiling provides comprehensive summary of mRNA levels in a tissue sample, allowing for identification of the sets of genes and transcripts associated with individual condition. Microarray studies of human diseases are often limited by challenges in obtaining human tissues. Peripheral blood has become an attractive prime tissue for biomarker detection because of its critical role in immune response, metabolism, communication with cells and the extracellular matrix in almost all tissues and organs in the human body, as well as for the simplicity and low invasiveness of sample collection [1] .
en35 2 Study Design and Methods
Experimental design of this study aimed at identifying the genes associated with excess genetic risk for the incidence of acute myocardial infarction which is not necessarily captured through known clinical risk factors.
Forty five cases with confirmed diagnosis of acute myocardial infarction were enrolled between September 2006 and January 2011. The diagnosis had to satisfy the clinical criteria, ECG outcome and laboratory findings according to medical guidelines. Coronary angiography was performed in most patients. The cases had to be less than 80 years old and no subjects could be actively treated for cancer.
Venous blood samples were drawn from each subject enrolled. Paired controls were selected out of patients hospitalized for motoric complications with no evidence of coronary artery or peripheral artery disease, normal ECG and no history of stroke. They were matched to cases based on their gender, age (the controls could be up to 5 years older than cases), status of Type II diabetes mellitus and smoking status. These variables represent clinical and underlying genetic factors associated with the incidence of acute myocardial infarction. This study focuses on identifying the profiles associated with excess genetic risk which are not necessarily expressed through these risk factors.
Six months following the cardiac event cardiovascular survival status was assessed for all the cases. We hypothesized that the cases who have not survived the six months follow-up period (AMID6) and those who did (AMI) would each differ in their genetic make-up from the controls. We also hypothesized differences in genetic profiles between the two groups of cases (AIMD6 vs. AMI). While the average paired gene expression differences between the cases and their corresponding matched controls capture the primary prevention perspective, the differences between AMID6 and AMI reflect the secondary prevention point of view.
The study complies with the Declaration of Helsinki and was approved by the local ethics committee. All participants gave written informed consent. Basic descriptive characteristics of the data are provided in Tables 1 and 2  below and supplementary Table S10 in [44] .
Microarray Analysis
The study utilized Illumina microarray technology for analyzing gene expression intensities across the full human genome. Samples of peripheral whole blood were collected from all subjects using commercial 3 ml Vacutainer R sets with EDTA. The tubes were inverted several times and 2.4 ml of the content was immediately mixed with 7.6 ml RNAlater R (Applied Biosystems) in 15 ml tubes, stabilized blood samples were inverted several times until they were homogenous and the samples were stored in -70 • C. The RNA was isolated from 1.8 ml aliquot of stabilized blood with RiboPure T M -Blood Kit (Applied Biosystems, U.S.A.), precipitated and purified with GLOBINclear T M -Human kit (Applied Biosystems, U.S.A.). The quantification was made on Nanodrop (Thermo Scientific, U.S.A.) and the integrity of the RNA was measured on Bioanalyzer 2100 (Agilent Technologies Inc., U.S.A.). The cRNA was amplified using Illumina R TotalPrep T M RNA Amplification Kit, precipitated and controlled on Nanodrop (Thermo Scientific, U.S.A.) and Bioanalyzer 2100 (Agilent Technologies Inc., U.S.A.). The cRNA samples (1.5 µg) were hybridized on HumanWG-6 v2 Expression BeadChips (Illumina Inc., U.S.A.) according to manufacturer's protocol.
Statistical Analysis
Statistical analysis used the R system for statistical computing, graphics and data analysis [2] . We used several packages which are part of the Bioconductor project [3] . The 'beadarray' package [4] was used for reading in the gene expression data from Illumina analyzer scans, the 'BASH' method [5] was used to identify defective beads on Illumina chips. We adopted 'normal-exponential convolution' method [6] for separating background noise from the signal. The log 2 -transformed quantile-normalized gene expression intensities were modeled using two explanatory variables, the matched pair indicator and the sampling group indicator ('AMI', 'AMID6', 'Controls') using the 'limma' package accounting for correlated data due to several biologically replicated samples [7] . Applying the empirical Bayes approach to model fit rendered moderated t-tests for each transcript/gene and contrast of interest. Multiple testing issues were handled using the q-value approach [8] . The two principal contrasts of interest estimated the mean paired differences in gene expression intensities between the cases (AIMD6, AIM) and their matched controls, respectively. Of interest were also the gene expression differences between the two groups of cases. Statistical significance was reached for transcripts with q-value below 0.05, clinical significance was reached when the log 2 -fold change was greater or equal to 1 in absolute value.
To identify subsets of genes possessing predictive properties in independent samples we employed shrunken centroids approach [9] implemented in the 'Predictive Analysis for Microarrays' (PAM). Subsets of genes identified as differentially expressed using the limma package were further analyzed using PAM. The final sets of genes so identified are believed to possess predictive properties in independent samples, which were evaluated using bootstrapping. PAM modeling technique was also applied to the full genome.
RT-qPCR Validation
Modeling results were validated by RT-qPCR analysis which used available RNA samples from the four cases, their matched controls and 6 other randomly selected controls. The genes ADORA3, VNN3, IL18R1, IL18RAP, ERLIN1, FOS and ARG1 were quantified while 18S and HPRT were used as housekeeping references for each tested sample. Gene SPATC1 was selected as negative control.
Results

Limma Modeling Results
Comparing the matched controls with the cases who died from cardiovascular causes within six months following the cardiac event (contrast 'AMID6 vs. Controls') implicated 60 differentially expressed genes/transcripts which met the criteria of both statistical (q < 0.05) and clinical (|log 2 F C| ≥ 1) significance. Of those genes, 40 were up-and 20 down-regulated. Without regard to clinical significance, statistical significance was attained for 323 transcripts; see the Venn diagrams in Figure 1 .
Comparing the cases who survived the 6 months follow up period with their matched pair controls (contrast 'AMI vs. Controls') revealed no genes that would meet the above mentioned criteria for either statistically or clinically significant differential expression.
The population gene expression differences between the two groups of cases (contrast 'AMID6 vs. AMI') were associated with 14 transcripts which met the criteria of both statistical and clinical significance, out of which 4 were up-and 10 down-regulated. Statistical significance was observed for 60 genes/transcripts, out of which 13 were up-and 47 down-regulated.
Supplementary tables S1, S4 and S7 in [44] present a detailed view of limma modeling results assessing the three linear contrasts in gene expression intensities.
Predictive PAM Modeling
For all three types of contrasts considered in this study we were particularly looking for the candidate sets of genes which would possess predictive properties in independent samples. Therefore, the available samples were studied further using shrunken centroids approach. The corresponding results are summarized in Table 3 . With each contrast Table 3 presents two candidate sets of genes. The Set 1 resulted from further reducing the gene set obtained from the limma modeling using PAM while the Set 2 was obtained by applying the PAM technique to all 39 226 available transcripts. Grey shading accentuates simultaneous presence of both statistical and clinical significance, as defined for this study. Comprehensive results covering the full genome reduction using PAM may be found in supplementary tables S3, S6 and S9 in [44] , tables S2, S5 and S8 in [44] show PAM reduction of the gene sets obtained using limma.
AMID6 vs. Controls
Applying the shrunken centroids technique to the set of both statistically and clinically significant transcripts identified via limma modeling (top 60 genes of Table S1 in [44] ) rendered 16 genes (Set 1) with predictive properties in independent samples shown in Table 3 . Initiating the PAM modeling with the full genome resulted in a set of 14 genes (Set 2) of which only IL18R1 and DUSP1 would not pass the criterion of statistical significance within limma modeling framework while adhering to the clinical one in all instances. Remarkably, the two corresponding sets have a large proportion of genes in common.
AMI vs. Controls
The set of genes obtained using limma modeling for this contrast (Table S4 in [44] ) did not exhibit statisti-cal or clinical significance as defined for our study and could not be further reduced using PAM modeling. The set obtained by applying the PAM technique to the full genome was quite extensive, counting 228 transcripts. Table 3 presents truncated list of top thirteen genes (Set 2) which includes five genes from the corresponding Set 1.
AMID6 vs. AMI
PAM reduction of 14 statistically and clinically significant transcripts identified via limma modeling (see Table S7 in [44] ) rendered 11 predictive transcripts, two of which pertain to gene 'CLYBL'. Initiating the PAM analysis with the full genome resulted in a set of 22 transcripts, four of which also appeared in the corresponding Set 1. Table 4 presents estimates of sensitivity and specificity of the PAM classifier obtained from three bootstrap studies evaluating predictive properties of the two sets of genes identified for each contrast of interest. The studies used 1000 samples from the target population with replacement. We report the mean values along with the 5 th and 95 th percentile for both quantities of interest.
Predictive properties assessed using the PAM classifier appeared generally more favorable when the gene sets 2 were employed while notable improvements were observed in relation to sensitivity rather than specificity. Some improvements, however, came at a price of large number of genes required. This was the case of contrast 'AMI vs. Controls' where the Set 1 was of size 13 while the Set 2 counted 228 transcripts. This is a likely consequence of having observed no statistically or clinically significant c 2012 EuroMISE s.r.o.
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RT-qPCR Validation Study
Results of the RT-qPCR validation are summarized in supplementary Table S12 in [44] . One observation in the AIMD6 group of cases (ID=C078) appeared fairly similar to controls, its removal lead to the overall improvement. Details concerning the subjects from AMID6 group are shown in supplementary Table S11 and S12 in [44] presents the summary of validation study results.
Discussion
AMI vs. Controls
This contrast identifies genes which were differentially expressed between general population and the cases who survived the six months follow-up period following the MI episode. Although no statistically significant results were obtained for this contrast, several genes shown in Table 3 were previously linked to MI and cardiovascular or coronary artery disease. The FOS gene plays a role in functional organization of central cardiovascular pathways; its expression in certain central neurons may lead to sustained changes in cardiovascular function [10] . VNN3 is part of pantetheinase gene family which regulates hydrolysis of pantetheine into pantothenic acid (vitamin B5) and cysteamine, a potent antioxidant. Human neutrophils express transcripts encoding multiple splice variants of VNN3 [11] . In relation to oxidative stress VNN3 may play a role in tissue repair [12] . Phosphorylation of clock protein PER1 was shown to regulate its circadian degradation in normal human fibroblasts [13] . Mutations in the LIPA gene were shown to be related to cholesterol metabolism [14] and the gene was described as susceptibility gene for the incidence of coronary artery disease [15, 16] . Genes OLIG1 and OLIG2 encode transcription factors expressed in both the developing and mature vertebrate central nervous system and may have additional functions in a variety of neurological diseases [17] . Wojakowski et al [18] report up-regulation of OLIG2 in stroke patients. Inouye et al [19] report gene MS4A3 as one of only three strong predictors of lipid leukocyte module from their genomewide study. Other genes showing significant evidence of association with lipid traits identified also in our study using PAM reduction of the whole genome include GATA2, CPA3, C1ORF186, C1ORF150, SLC45A3, SPRYD5 and CEBPD ( Supplementary Table S6 in [44] ), all with potential contribution to the pathogenesis of coronary artery disease. Gene EPAS1 was identified as a significant promoter of angiogenesis [20] . Castillo et al [21] demonstrated that inflammatory chemokine CCL23 is independently associated with coronary atherosclerosis. The MYB gene plays essential role in adult vascular smooth muscle cells survival [22] .
AMID6 vs. Controls
This contrast targets differentially expressed genes among the cases not surviving the 6 months follow-up relative to general population. All predictive genes of the Set 2 in Table 3 have shown both clinically and statistically significant differential expression based on limma modeling. Gene ADORA3 is known as a receptor mediating cardioprotective functions during ischemia [23] . In our study the gene was overexpressed in cases that died within 6 months from cardiovascular complications relative to controls. The same was true relative to surviving cases ('AIMD6 vs. AMI') while the gene was under expressed among surviving cases relative to controls (supplementary Table S6 in [44] ). Increased activity may be observed with genes involved in the overall immune response (IL18R1, IL18RAP). Liangos et al [24] uncovered highly intertwined signaling underlying ischemia reperfusion and inflammatory response. The corresponding genes identified in our study include IL18R1, IL18RAP, IL1RAP, LCN2 and TLR4 (tables S1 and S6 in [44] ). Mallat et al [25] report significant expression of proinflammatory cytokine IL-18 and its signaling receptor IL-18R in human atherosclerotic plaques. Rosenberg et al [26] validated diagnostic test based on the expression of 23 genes previously found to be associated with the presence of CAD. From the genes they used in predictive modeling those identified in our study involve IL18RAP, TLR4 and CLEC4E, a mediator of immune and inflammatory re- [27] related genetic variability in IL18, IL18R1 and IL18RAP to cardiovascular mortality. The gene SAMSN1 was found to be preferentially expressed in mast cells [28] containing large amounts of heparin and histamine. Protein encoded by the PFKFB2 gene mediates control of glycolysis in eukaryotes. IRS2 gene was shown to be associated with severe obesity and insulin sensitivity in Type II diabetic patients [29, 30] . The gene VNN3 reappears also with this contrast. Gene PHACTR1 was cited for the association with CAD, CVD and MI based on several recent genome-wide studies [31, 32] . The ERLIN1 gene was recently identified as a member of the prohibitin family of proteins that define lipid-raft-like domains of the ER [33] . Polymorphisms in FKBP5 may be associated with increased vulnerability to posttraumatic stress disorder [34] . Gene PRKDC is a central regulator of DNA double-strand break repair. Down-regulation of NPM1 was previously linked to cardiac cell differentiation [35] , the DUSP1 gene was found to be associated with oxidative stress response [36] . No references in relation to CVD, CAD or MI could be found for the genes ECHDC3 and ASPRV1.
AMID6 vs. AMI
This contrast signifies population gene expression differences between the surviving cases and those who died within 6 months following the acute MI episode. Both statistical and clinical significance based on limma modeling was attained for Set 1. Several predictive genes are repeated here from the 'AIMD6 vs. Controls' contrast. They include ADORA3, IL18RAP, ERLIN1, AS-PRV1, gene TCRB is repeated from 'AIM vs. Controls'. Strongly down-regulated genes TCRA, TCRB and AXIN2 participate in V(D)J recombination, T-cell and leukocyte differentiation, antibody-dependent cellular cytotoxicity and signal transduction. Dumont et al [37] report association of ARG1 polymorphisms with the risk of AMI and common carotid intima media thickness. Harpster et al [38] report ARG1 as the single most highly induced transcript in post-myocardial infarction subjects. Complement regulator CD59 is a potent inhibitor of the membrane attack complex (MAC). Acosta et al suggest that in diabetes glycation-inactivation of endothelial CD59 would contribute to the development of vascular complications [39] . CD59 was shown to protect against atherosclerosis by restricting the MAC formation [40] . Transcription factor ETS2 was recently identified to determine inflammatory state of endothelial cells in advanced atherosclerotic lesions [41] . Meta-analysis of 15 GWAS studies [42] revealed a few genes associated with resting heart rate, a predictor of cardiovascular mortality, including BCAT1 gene.
Number of genes and transcripts identified in our study as being associated with the outcome represent novel candidates which were not previously linked to the incidence of acute myocardial infarction. We illustrate four up-regulated (AMPH, FLT3, ZNF516) and five down-regulated genes (AXIN2, CLYBL, KIF20B, TCEA3, TCRA) identified in our study. Amphiphysinsynaptic vesicle-associated protein (AMPH) observed in Stiff-Man syndrome includes SH3 domains in C-terminal region. Up-regulated activity of the gene FLT3 is linked to hematopoiesis activation, angiogenesis, hematopoietic progenitor cell differentiation, macrophage differentiation and interleukin, natural killer activation. ZNF516 (zinc finger protein 516) is a gene family member, coordinating Zn-ions in stabilizing different cellular processes. AXIN2 plays important role in beta-catenin stabilization. CLYBL encodes beta-like citrate lyase. KIF20B, kinesin family member 20B, is a structure required for completion of cytokinesis. The group of down-regulated genes includes the gene TCEA3 providing interaction with the enzyme RNA polymerase II during the transcription process. TCRA is a T-cell antigen receptor, alpha-subunit.
Furthermore, we identified novel up-regulated (LOC645649, c13orf18, AW337887, c7orf53, c2orf58, CN484989) and down-regulated structures (LOC130951, CR596519, BM682470, CR592039, X00437) that are listed in Table 3 . Recently, Puigdecanet et al [43] identified C13orf18 being part of a molecular signature characterized with an upregulation of inflammatory genes related to neutrophil activation and thrombosis.
Text mining search of medical literature performed at PubGene.com using MeSH term 'Myocardial Infarction' and the set of genes found to be predictive for MI (see Table 3 ) rendered 10 genes most cited for their association with MI plus four genes (ADORA3, FOS, ARG1, CD 59) indicated in our study which appear to be related to these genes. Figure 2 shows that the four genes are linked to positive regulation of Interleukin 12 production (ADORA3), co-regulation of insulin secretion (FOS), regulation of reverse cholesterol transport, co-regulation of insulin secretion, cholesterol absorption, cardiac muscle contraction and glycoprotein biosynthetic process (ARG1) and activation of membrane attack complex (CD59). Supplementary Figure S1 in [44] uncovers relationships of these four genes with other genes. Biological processes associated with the genes shown in Table 3 are summarized in supplementary Table S13 in [44] .
Only a partial agreement with the gene sets reported to be associated with the incidence of MI from other studies may in part be explained by the differences in statistical design, studied population and respective sample sizes, use of non-homogenous subgroups (diabetics, nondiabetic patients), population distributions of related risk factors, therapy (especially use of statins), exclusion criteria, existence of concomitant diseases and other inflammatory conditions, heart failure, smoking, extent of non-coronary atherosclerosis, and examination of circulating cells and other cells in tissues.
Due to significant costs involved in microarray analysis our study is limited by a relatively small sample size. Synthesis of the genetic and clinical information gathered from genomic studies is expected to refine personalized approaches to managing the risk of CAD. Genetic risk scores Table 3 .
derived from several functional single nucleotide polymorphisms (SNPs) or haplotypes in multiple genes may improve the prediction of CAD.
